RU2013108256A - Дисперсии цитрата разагилина - Google Patents

Дисперсии цитрата разагилина Download PDF

Info

Publication number
RU2013108256A
RU2013108256A RU2013108256/15A RU2013108256A RU2013108256A RU 2013108256 A RU2013108256 A RU 2013108256A RU 2013108256/15 A RU2013108256/15 A RU 2013108256/15A RU 2013108256 A RU2013108256 A RU 2013108256A RU 2013108256 A RU2013108256 A RU 2013108256A
Authority
RU
Russia
Prior art keywords
rasagiline
solid dispersion
solvent
pharmaceutical excipient
pharmaceutically acceptable
Prior art date
Application number
RU2013108256/15A
Other languages
English (en)
Russian (ru)
Inventor
Кит Лоример
Дэвид ЭНДЖЕРС
Original Assignee
Тева Фармасьютикал Индастриз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз Лтд. filed Critical Тева Фармасьютикал Индастриз Лтд.
Publication of RU2013108256A publication Critical patent/RU2013108256A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2013108256/15A 2010-07-27 2011-07-27 Дисперсии цитрата разагилина RU2013108256A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40036910P 2010-07-27 2010-07-27
US61/400,369 2010-07-27
PCT/US2011/045569 WO2012015946A1 (en) 2010-07-27 2011-07-27 Dispersion of rasagiline citrate

Publications (1)

Publication Number Publication Date
RU2013108256A true RU2013108256A (ru) 2014-09-10

Family

ID=45530490

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013108256/15A RU2013108256A (ru) 2010-07-27 2011-07-27 Дисперсии цитрата разагилина

Country Status (7)

Country Link
US (2) US8691872B2 (enExample)
EP (1) EP2598136A4 (enExample)
JP (1) JP2013537530A (enExample)
AU (1) AU2011282716A1 (enExample)
CA (1) CA2806737A1 (enExample)
RU (1) RU2013108256A (enExample)
WO (1) WO2012015946A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1991214B1 (en) * 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
EP2007369A4 (en) 2006-04-03 2009-07-01 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
EA016820B1 (ru) * 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Кристаллическое твердое основание разагилина
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
NZ586025A (en) * 2008-01-11 2012-08-31 Teva Pharma Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
ES2389353T3 (es) * 2008-06-10 2012-10-25 Teva Pharmaceutical Industries Ltd. Cápsulas de gelatina blanda de rasagilina
RS53504B1 (sr) 2009-07-09 2015-02-27 Ratiopharm Gmbh Soli razagilina i njihovi farmaceutski preparati
US20110130466A1 (en) * 2009-10-09 2011-06-02 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
EP2939669A1 (en) * 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
KR20140090996A (ko) 2011-10-10 2014-07-18 테바 파마슈티컬 인더스트리즈 리미티드 R(+)-n-폼일-프로파길-아미노인단
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤
WO2020098774A1 (zh) * 2018-11-16 2020-05-22 江苏恒瑞医药股份有限公司 一种包含parp抑制剂的药物组合物
WO2022162612A1 (en) 2021-01-30 2022-08-04 Intas Pharmaceuticals Ltd. An orodispersible pharmaceutical solid dosage form of rasagiline
EP4035654A1 (en) 2021-01-30 2022-08-03 Intas Pharmaceuticals Limited An orodispersible pharmaceutical solid dosage form of rasagiline

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DE69732984T2 (de) 1996-12-18 2006-02-16 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
EP2526944B1 (en) 2002-11-15 2016-06-01 Teva Pharmaceutical Industries Limited Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
CA2547657A1 (en) * 2003-12-01 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising lercanidipine
EP1778196A4 (en) 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
CN101098685A (zh) 2004-11-24 2008-01-02 特瓦制药工业有限公司 雷沙吉兰经口崩解组合物
KR20140103356A (ko) 2005-02-23 2014-08-26 테바 파마슈티컬 인더스트리즈 리미티드 함량 균일성이 개선된 라사길린 제형
EP1954667B1 (en) 2005-11-17 2017-02-08 Teva Pharmaceutical Industries Ltd Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
EP1991214B1 (en) 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
CN101032474B (zh) 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP2007369A4 (en) 2006-04-03 2009-07-01 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
WO2008076315A1 (en) 2006-12-14 2008-06-26 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
EA016820B1 (ru) 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Кристаллическое твердое основание разагилина
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
EP2194780A4 (en) 2007-09-05 2010-10-27 Teva Pharma METHOD FOR TREATING GLAUCOMA BY RASAGILINE
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
NZ586025A (en) 2008-01-11 2012-08-31 Teva Pharma Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
ES2389353T3 (es) 2008-06-10 2012-10-25 Teva Pharmaceutical Industries Ltd. Cápsulas de gelatina blanda de rasagilina
JP2011522892A (ja) 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
CA2727021A1 (en) 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
WO2009154777A2 (en) 2008-06-19 2009-12-23 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
EP2218444A3 (en) * 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US8080584B2 (en) 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
RS53504B1 (sr) 2009-07-09 2015-02-27 Ratiopharm Gmbh Soli razagilina i njihovi farmaceutski preparati
US20110130466A1 (en) 2009-10-09 2011-06-02 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
EP2939669A1 (en) 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
EA201390613A1 (ru) 2010-10-26 2013-11-29 Тева Фармасьютикал Индастриз Лтд. Обогащенный дейтерием расагилин
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
US20130089611A1 (en) 2011-10-10 2013-04-11 Teva Pharmaceutical Industries, Ltd. Rasagiline citramide
KR20140090996A (ko) 2011-10-10 2014-07-18 테바 파마슈티컬 인더스트리즈 리미티드 R(+)-n-폼일-프로파길-아미노인단

Also Published As

Publication number Publication date
CA2806737A1 (en) 2012-02-02
US20140194510A1 (en) 2014-07-10
AU2011282716A1 (en) 2013-03-14
JP2013537530A (ja) 2013-10-03
US8691872B2 (en) 2014-04-08
WO2012015946A1 (en) 2012-02-02
EP2598136A4 (en) 2015-03-25
WO2012015946A8 (en) 2013-01-31
EP2598136A1 (en) 2013-06-05
US20120059058A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
RU2013108256A (ru) Дисперсии цитрата разагилина
JP2013537530A5 (enExample)
JP2009530415A5 (enExample)
RU2017106795A (ru) Новые составы ингибитора тирозинкиназы брутона
WO2016038532A1 (en) Amorphous treprostinil diethanolamine
JP2012236837A5 (enExample)
JP2009530416A5 (enExample)
HRP20221355T1 (hr) Liofilizirani pripravak citotoksičnih dipeptida
JP2013532035A5 (enExample)
NO321523B1 (no) Preparat omfattende et nitroksyderivat, farmasoytisk formulering inneholdende dette og fremgangsmate for fremstilling av preparatet.
KR101895962B1 (ko) 알리사르탄 이소프록실 고체 분산체 및 이를 포함하는 약제학적 조성물
RU2009137911A (ru) Порошки для создания жирной лекарственной формы
US20190083627A1 (en) Pharmaceutical Composition Containing Tacrolimus and Preparation Methods Thereof
WO2017163190A1 (en) Amorphous ixazomib citrate and solid dispersion thereof
CN102178642A (zh) 一种替米沙坦固体分散体及其制备方法
CN108186597A (zh) 一种鲁比前列酮固体分散体及其制备方法
CN102871994B (zh) 氟比洛芬对乙酰氨基酚酯环糊精包合物及其制备方法
CN102977039B (zh) 6-氟-3-羟基-2-吡嗪甲酰胺α晶型及其制备方法
CN106619503B (zh) 一种大黄酸酰胺类衍生物纳米混悬剂及其制备方法和应用
CN112972380B (zh) 一种多功能新型给药系统制剂的制备方法及应用
JP2016006090A (ja) レボノルゲストレルの結晶多形α及びその製造方法
CN102813639A (zh) 甲苯达唑软胶囊剂
CN102641240A (zh) 一种苦柯胺b盐注射剂及其制备方法
CN103494809B (zh) 一种包含罗匹尼罗的组合物的制备方法
CN105434378B (zh) 美索舒利分散片及其制备方法

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20160122